Evidence map›Paper›PMID 36968112›Full record

ArticleFrontiers in cellular and infection microbiology2023

Serological surveillance on potential

Fang Huang, Yanwen Cui, Zhuoying Huang, Siqi Wang, Shigang Li, Xiangrui Guo, Xiang Guo, Zhi-Gui Xia

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fang HuangInstitute of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Yanwen CuiDivision of Tuberculosis Control and Prevention, Shanghai Pudong Center for Disease Control and Prevention, Shanghai, China.
Zhuoying HuangInstitute of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Siqi WangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China.
Shigang LiDivision of Endemic Disease Control and Prevention, Yingjiang County Center for Disease Control and Prevention, Yingjiang, China.
Xiangrui GuoDivision of Endemic Disease Control and Prevention, Yingjiang County Center for Disease Control and Prevention, Yingjiang, China.
Xiang GuoInstitute of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Zhi-Gui XiaNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China.
Shanghai Municipal Center For Disease Control Prevention · CNNational Institute for Parasitic Diseases · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

China was declared malaria free in June of 2021. In the post-elimination setting, vigilant surveillance is essential to sustain malaria free status. Serological surveillance has been recognized as an efficient tool for assessing the immunity levels and exposure risk in a population. In this study, a cross-sectional serological survey was conducted in Yingjiang County, China, in August-September, 2021. The study sites were villages along the borders with Myanmar, which have no local transmission since the last indigenous case registered in 2016. A total of 923 participants from six villages were enrolled. The majority was aged > 36 years (56.12%) and 12.46% (115/923) participants had experienced malaria infection at least once. A magnetic- bead-based assay was used to test antibodies against

Indexed as

MalariaMalaria, FalciparumMalaria, VivaxAntibodies, ProtozoanCross-Sectional StudiesHumansImmunoglobulin GPlasmodium falciparumPlasmodium vivaxSeroepidemiologic StudiesAntibodies, ProtozoanImmunoglobulin Ganti-PvMSP-1 IgGChinaPlasmodium vivaxpost-elimination settingserological surveillance

Identifiers

PMID36968112
PMCPMC10034364
OpenAlexW4323665348

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read28
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.